Spots Global Cancer Trial Database for chimeric antigen receptor
Every month we try and update this database with for chimeric antigen receptor cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma | NCT06429150 | Multiple Myelom... Plasmacytoma | CAR-T cells | 18 Years - 80 Years | Shenzhen Geno-Immune Medical Institute | |
| Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001) | NCT02631044 | Non-Hodgkin Lym... Diffuse Large B... Follicular Lymp... Mantle-cell Lym... Primary Mediast... | JCAR017 (lisoca... JCAR017 (lisoca... | 18 Years - | Juno Therapeutics, a Subsidiary of Celgene | |
| PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma | NCT05172596 | Multiple Myelom... | PHE885 | 18 Years - | Novartis | |
| Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients | NCT04844866 | Diffuse Large B... | MB-CART2019.1 R-GemOx or BR p... | 18 Years - | Miltenyi Biomedicine GmbH | |
| Safety and Efficiency Study of BCMA-PD1-CART Cells in Relapsed/Refractory Multiple Myeloma | NCT04162119 | Multiple Myelom... | BCMA-PD1-CART C... | 14 Years - 80 Years | Chinese PLA General Hospital | |
| Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant | NCT04815356 | Hairy Cell Leuk... Hairy Cell Leuk... | CD22CART cell i... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Anti-PD-L1 Armored Anti-CD22 CAR-T/CAR-TILs Targeting Patients With Solid Tumors | NCT04556669 | Solid Tumor, Ad... Cervical Cancer Sarcoma NSCLC | Autologous aPD-... | 18 Years - 75 Years | Hebei Senlang Biotechnology Inc., Ltd. | |
| A Clinical Study of IL13Rα2 Targeted CAR-T in Patients With Malignant Glioma (MAGIC-I) | NCT05540873 | Recurrent Malig... | YYB-103 | 19 Years - 74 Years | CellabMED | |
| CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR) | NCT03774654 | Refractory B-Ce... Refractory B-Ce... Relapsed Adult ... Relapsed CLL Relapsed Non Ho... | CD19.CAR-aNKT c... | 3 Years - 75 Years | Baylor College of Medicine | |
| PSMA-specific CAR-T Cell Therapy | NCT04429451 | PSMA Positive T... | 4SCAR-PSMA T ce... | 1 Year - 75 Years | Shenzhen Geno-Immune Medical Institute | |
| A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL | NCT05138458 | Lymphoma, T-Cel... Lymphoma, T-Cel... Mycosis Fungoid... Adoptive Cellul... Cell Therapy | MT-101 MT-101 + Condit... | 18 Years - | Myeloid Therapeutics | |
| Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System | NCT04561557 | Autoimmune Dise... Autoimmune Dise... Neuromyelitis O... Myasthenia Grav... Chronic Inflamm... Idiopathic Infl... Multiple Sclero... Autoimmune Ence... Myelin Oligoden... POEMS Syndrome | CT103A cells Cyclophosphamid... | 18 Years - 75 Years | Tongji Hospital | |
| Study of CD19 Specific Chimeric Antigen Receptor Positive T Cells (CAR-T) in ALL and NHL | NCT04206943 | Acute Lymphobla... Non Hodgkin Lym... | Car-T Cell Ther... | 3 Years - 65 Years | Acibadem University | |
| CTL019 Out of Specification MAP for ALL or DLBCL Patients | NCT03601442 | Acute Lymphobla... Diffuse Large B... | CTL019 | 1 Day - 25 Years | Novartis | |
| Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma | NCT03430011 | Multiple Myelom... | JCARH125 JCARH125 + anak... | 18 Years - | Juno Therapeutics, a Subsidiary of Celgene | |
| Clinical Study of PSMA-targeted CAR-T Cells in the Treatment of Castration-resistant Prostate Cancer | NCT05354375 | Immunotherapy | CAR-T cell immu... | 18 Years - 75 Years | The Affiliated Hospital of Xuzhou Medical University | |
| Safety and Efficiency Study of BCMA-PD1-CART Cells in Relapsed/Refractory Multiple Myeloma | NCT04162119 | Multiple Myelom... | BCMA-PD1-CART C... | 14 Years - 80 Years | Chinese PLA General Hospital | |
| A Phase I/IIa Clinical Trial to Assess Feasibility, Safety and Antitumor Activity of Autologous SLAMF7 CAR-T Cells in Multiple Myeloma | NCT04499339 | Multiple Myelom... | SLAMF7 CAR-T | 18 Years - | Wuerzburg University Hospital | |
| Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells for Relapsed or Refractory Solid Tumour | NCT04107142 | Colorectal Canc... Triple Negative... Sarcoma Nasopharyngeal ... Prostate Cancer Gastric Cancer | Adoptive Cell T... | 18 Years - | CytoMed Therapeutics Pte Ltd | |
| Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia | NCT03573700 | Acute Lymphobla... Acute Lymphobla... | Cyclophosphamid... Fludarabine Mesna CliniMACS CD19- specific ... | - 21 Years | St. Jude Children's Research Hospital | |
| A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed/Refractory B-cell Malignancies | NCT03310619 | Lymphoma, Non-H... Lymphoma, Large... Lymphoma, Folli... | JCAR017 Durvalumab CC-122 Ibrutinib CC-220 Relatlimab Nivolumab CC-99282 | 18 Years - | Celgene | |
| Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU | NCT06116110 | Non Hodgkin Lym... | Long-term Follo... | 18 Years - | Miltenyi Biomedicine GmbH | |
| Clinical Study of CAIX-targeted CAR-T Cells in the Treatment of Advanced Renal Cell Carcinoma | NCT04969354 | Immunotherapy | CAR-T cell immu... | 18 Years - 70 Years | The Affiliated Hospital of Xuzhou Medical University | |
| PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma | NCT05172596 | Multiple Myelom... | PHE885 | 18 Years - | Novartis | |
| A Phase I/IIa Clinical Trial to Assess Feasibility, Safety and Antitumor Activity of Autologous SLAMF7 CAR-T Cells in Multiple Myeloma | NCT04499339 | Multiple Myelom... | SLAMF7 CAR-T | 18 Years - | Wuerzburg University Hospital | |
| Clinical Study of PSMA-targeted CAR-T Cells in the Treatment of Castration-resistant Prostate Cancer | NCT05354375 | Immunotherapy | CAR-T cell immu... | 18 Years - 75 Years | The Affiliated Hospital of Xuzhou Medical University | |
| Pilot Study of T-APCs Following CAR T Cell Immunotherapy for CD19+ Leukemia | NCT03186118 | CD 19+ Acute Le... | T-cell Antigen ... | 1 Year - 30 Years | Seattle Children's Hospital | |
| Intracerebral EGFR-vIII CAR-T Cells for Recurrent GBM | NCT03283631 | Recurrent Gliob... Recurrent Glios... | EGFRvIII-CARs | 18 Years - | Duke University | |
| Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG) | NCT04146051 | Myasthenia Grav... | Descartes-08 | 18 Years - | Cartesian Therapeutics | |
| A Phase I Trial of Anti-GD2 T-cells (1RG-CART) | NCT02761915 | Relapsed or Ref... | Leukapheresis Cyclophosphamid... Fludarabine 1RG-CART | 1 Year - | Cancer Research UK | |
| Haplo / Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells for Relapsed or Refractory Solid Tumour | NCT04107142 | Colorectal Canc... Triple Negative... Sarcoma Nasopharyngeal ... Prostate Cancer Gastric Cancer | Adoptive Cell T... | 18 Years - | CytoMed Therapeutics Pte Ltd | |
| Phase I Study of pCAR-19B in the Treatment of Adult CD19-positive Relapsed/Refractory B-ALL | NCT04888442 | Acute Lymphobla... Refractory Acut... | pCAR-19B cells | 22 Years - 70 Years | Chongqing Precision Biotech Co., Ltd | |
| Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma Patients | NCT04836507 | Relapsed Large ... Refractory Larg... Diffuse Large B... Primary Mediast... High-grade B-ce... Transformed Fol... | CRC01 Fludarabine Cyclophosphamid... | 19 Years - | Curocell Inc. | |
| Efficacy and Safety of Tisagenlecleucel in Adult Patients With Refractory or Relapsed Follicular Lymphoma | NCT03568461 | Follicular Lymp... | tisagenlecleuce... | 18 Years - | Novartis | |
| Clinical Study of CAIX-targeted CAR-T Cells in the Treatment of Advanced Renal Cell Carcinoma | NCT04969354 | Immunotherapy | CAR-T cell immu... | 18 Years - 70 Years | The Affiliated Hospital of Xuzhou Medical University | |
| 3RD GENERATION GD2 SPECIFIC CHIMERIC ANTIGEN RECEPTOR TRANSDUCED AUTOLOGOUS NATURAL KILLER T-CELLS FOR NEUROBLASTOMA | NCT02439788 | Neuroblastoma | cyclophosphamid... Fludarabine GINAKIT Cells | 1 Year - 18 Years | Baylor College of Medicine | |
| A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007) | NCT03744676 | Lymphoma, Non-H... Lymphoma Lymphoma, B-Cel... Lymphoma, Large... Neoplasms Neoplasms by Hi... Lymphoprolifera... Lymphatic Disea... Immunoprolifera... Immune System D... | lisocabtagene m... | 18 Years - | Juno Therapeutics, a Subsidiary of Celgene | |
| CART19 Cells Effects in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma | NCT05054257 | Relapsed or Ref... Non-Hodgkin's L... Non-Hodgkin's L... | Autologous CAR1... | 18 Years - 80 Years | Institute of Hematology and Blood Transfusion, Czech Republic | |
| Phase I Study of pCAR-19B in the Treatment of Adult CD19-positive Relapsed/Refractory B-ALL | NCT04888442 | Acute Lymphobla... Refractory Acut... | pCAR-19B cells | 22 Years - 70 Years | Chongqing Precision Biotech Co., Ltd | |
| Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001) | NCT02631044 | Non-Hodgkin Lym... Diffuse Large B... Follicular Lymp... Mantle-cell Lym... Primary Mediast... | JCAR017 (lisoca... JCAR017 (lisoca... | 18 Years - | Juno Therapeutics, a Subsidiary of Celgene | |
| A Pediatric Trial of Genetically Modified Autologous T Cells Directed Against CD19 for Relapsed CD19+ Acute Lymphoblastic Leukemia | NCT01683279 | B Cell Leukemia | Autologous CD19... | 1 Year - 26 Years | Seattle Children's Hospital | |
| Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO) | NCT02050347 | Non-Hodgkin's L... B-Cell ALL B-Cell CLL | CD19.CAR-CD28Z ... CD19.CAR-CD28Z ... | - | Baylor College of Medicine | |
| 4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma | NCT04637503 | Neuroblastoma | GD2, PSMA and C... | 1 Year - 65 Years | Shenzhen Geno-Immune Medical Institute | |
| CTL019 Out of Specification MAP for ALL or DLBCL Patients | NCT03601442 | Acute Lymphobla... Diffuse Large B... | CTL019 | 1 Day - 25 Years | Novartis | |
| Long-term Follow-up Study of Patients Receiving CAR-T Cells | NCT03375619 | Chronic Lymphoc... Lymphomas Non-H... Lymphoma, Small... Mantle Cell Lym... Central Nervous... Diffuse Large B... Follicular Lymp... Burkitt Lymphom... Multiple Myelom... | Long-Term Follo... | 18 Years - 80 Years | Medical College of Wisconsin | |
| C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N) | NCT03635632 | Relapsed Neurob... Refractory Neur... Relapsed Osteos... Relapsed Ewing ... Relapsed Rhabdo... Uveal Melanoma Phyllodes Breas... | C7R-GD2.CART ce... | 1 Year - 74 Years | Baylor College of Medicine | |
| MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma | NCT04555551 | Multiple Myelom... | Infusion of MCA... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Safety and Efficacy of CS1 CAR-T (WS-CART-CS1) in Subjects With Multiple Myeloma | NCT06185751 | Multiple Myelom... | WS-CART-CS1 Lymphodepleting... | 18 Years - | Washington University School of Medicine | |
| Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma | NCT06429150 | Multiple Myelom... Plasmacytoma | CAR-T cells | 18 Years - 80 Years | Shenzhen Geno-Immune Medical Institute | |
| A Phase I/IIa Clinical Trial to Assess Feasibility, Safety and Antitumor Activity of Autologous SLAMF7 CAR-T Cells in Multiple Myeloma | NCT04499339 | Multiple Myelom... | SLAMF7 CAR-T | 18 Years - | Wuerzburg University Hospital | |
| Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients | NCT04844866 | Diffuse Large B... | MB-CART2019.1 R-GemOx or BR p... | 18 Years - | Miltenyi Biomedicine GmbH | |
| A Phase 1 Study of CD22-CAR TCell Immunotherapy for CD22+ Leukemia and Lymphoma | NCT03244306 | Leukemia | Patient-derived... | 1 Year - 26 Years | Seattle Children's Hospital | |
| Study on GD2 Positive Solid Tumors by 4SCAR-GD2 | NCT02992210 | Solid Tumor | 4SCAR-GD2 | 1 Year - 65 Years | Shenzhen Geno-Immune Medical Institute | |
| 4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma | NCT04637503 | Neuroblastoma | GD2, PSMA and C... | 1 Year - 65 Years | Shenzhen Geno-Immune Medical Institute | |
| A Phase 1 Study of CD22-CAR TCell Immunotherapy for CD22+ Leukemia and Lymphoma | NCT03244306 | Leukemia | Patient-derived... | 1 Year - 26 Years | Seattle Children's Hospital | |
| Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic Leukemia | NCT03155191 | Lymphoblastic L... | TBI-1501 | 16 Years - | Takara Bio Inc. | |
| A Pediatric Trial of Genetically Modified Autologous T Cells Directed Against CD19 for Relapsed CD19+ Acute Lymphoblastic Leukemia | NCT01683279 | B Cell Leukemia | Autologous CD19... | 1 Year - 26 Years | Seattle Children's Hospital | |
| A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL | NCT05138458 | Lymphoma, T-Cel... Lymphoma, T-Cel... Mycosis Fungoid... Adoptive Cellul... Cell Therapy | MT-101 MT-101 + Condit... | 18 Years - | Myeloid Therapeutics | |
| Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System | NCT04561557 | Autoimmune Dise... Autoimmune Dise... Neuromyelitis O... Myasthenia Grav... Chronic Inflamm... Idiopathic Infl... Multiple Sclero... Autoimmune Ence... Myelin Oligoden... POEMS Syndrome | CT103A cells Cyclophosphamid... | 18 Years - 75 Years | Tongji Hospital | |
| Anti-GD2 4th Generation CART Cells Targeting Refractory and/or Recurrent Neuroblastoma | NCT02765243 | Neuroblastoma Effects of Immu... | Anti-GD2 CART | 1 Year - 14 Years | Zhujiang Hospital | |
| A Study Evaluating UCART019 in Patients With Relapsed or Refractory CD19+ Leukemia and Lymphoma | NCT03166878 | B Cell Leukemia B Cell Lymphoma | UCART019 | 12 Years - 75 Years | Chinese PLA General Hospital | |
| BCMA-directed CAR-T Cell Therapy in Adult Patients With Multiple Myeloma | NCT04318327 | Multiple Myelom... | PHE885 | 18 Years - | Novartis | |
| Anti-GD2 4th Generation CART Cells Targeting Refractory and/or Recurrent Neuroblastoma | NCT02765243 | Neuroblastoma Effects of Immu... | Anti-GD2 CART | 1 Year - 14 Years | Zhujiang Hospital | |
| Study of CD19 Specific Chimeric Antigen Receptor Positive T Cells (CAR-T) in ALL and NHL | NCT04206943 | Acute Lymphobla... Non Hodgkin Lym... | Car-T Cell Ther... | 3 Years - 65 Years | Acibadem University | |
| Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies | NCT02315612 | NHL Large Cell Lymp... Follicular Lymp... ALL B-All B-precursor ALL Acute Lymphobla... Acute Lymphocyt... B-Non Hodgkin L... B-NHL | CD22-CAR | 3 Years - 39 Years | National Institutes of Health Clinical Center (CC) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
